| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STX4 |
| Uniprot No | Q12846 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-275aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMMRDRT HELRQGDDSS DEEDKERVAL VVHPGTARLG SPDEEFFHKV RTIRQTIVKL GNKVQELEKQ QVTILATPLP EESMKQELQN LRDEIKQLGR EIRLQLKAIE PQKEEADENY NSVNTRMRKT QHGVLSQQFV ELINKCNSMQ SEYREKNVER IRRQLKITNA GMVSDEELEQ MLDSGQSEVF VSNILKDTQV TRQALNEISA RHSEIQQLER SIRELHDIFT FLATEVEMQG EMINRIEKNI LSSADYVERG QEHVKTALEN QKKARKKKVL |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STX4重组蛋白的3篇参考文献示例(文献信息为虚构，仅供参考)：
---
**1. Title:** *Recombinant STX4 Enhances Glucose Uptake in Skeletal Muscle via GLUT4 Translocation*
**Authors:** Smith, J.R., Li, Y., & Chen, H.
**Summary:** 本研究利用重组STX4蛋白探究其在骨骼肌细胞GLUT4囊泡转运中的作用。实验表明，外源性STX4通过促进SNARE复合体形成，显著增强胰岛素刺激下的GLUT4膜融合，改善2型糖尿病小鼠模型的胰岛素敏感性。
---
**2. Title:** *Structural Characterization of STX4 Recombinant Protein and Its Role in Exocytosis*
**Authors:** Zhang, L., Wang, T., & Kumar, S.
**Summary:** 通过X射线晶体学解析了重组STX4蛋白的N端结构域，揭示了其与Munc18-1蛋白的互作机制。功能实验表明，重组STX4可恢复STX4敲除细胞的分泌缺陷，为膜融合机制提供了分子层面的证据。
---
**3. Title:** *Therapeutic Potential of STX4 Recombinant Protein in Cardiac Ischemia-Reperfusion Injury*
**Authors:** Gupta, A., Lee, S., & Park, J.
**Summary:** 研究评估了重组STX4蛋白在心肌缺血再灌注损伤中的保护作用。结果显示，STX4通过调控线粒体膜融合蛋白OPA1.减少细胞凋亡并改善心脏功能，提示其作为心脏疾病治疗靶点的潜力。
---
注：以上文献为示例性内容，实际研究中需检索真实数据库(如PubMed、Web of Science)获取具体文献。
**Background of STX4 Recombinant Protein**
Syntaxin 4 (STX4), a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) protein family, plays a critical role in intracellular vesicle trafficking and membrane fusion processes. It is predominantly localized to the plasma membrane, where it mediates the docking and fusion of transport vesicles, facilitating the secretion of cellular cargo and the recycling of membrane components. STX4 is particularly vital in glucose homeostasis, as it regulates the translocation of glucose transporter GLUT4 to the cell surface in adipocytes and muscle cells, a process essential for insulin-stimulated glucose uptake. Dysregulation of STX4 has been implicated in metabolic disorders, including type 2 diabetes and obesity.
Recombinant STX4 protein is engineered using heterologous expression systems, such as *E. coli* or mammalian cell cultures, to produce highly purified, functional protein for research and therapeutic applications. Its recombinant form retains the ability to interact with partner SNARE proteins (e.g., SNAP-23 and VAMP2), enabling studies on vesicle fusion mechanisms, membrane dynamics, and intracellular signaling pathways. Researchers utilize STX4 recombinant protein to investigate its role in insulin resistance, neuronal exocytosis, and immune cell function, as well as to screen potential therapeutics targeting SNARE-mediated processes.
The development of STX4 recombinant tools has advanced our understanding of cellular trafficking and its implications in disease, offering a platform for drug discovery and mechanistic studies in cell biology and metabolic research.
×
